Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04558307 · ClinicalTrials.gov registry record
Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1,000
- Enrollment target
NCT04558307: Completed study, sponsored by Mayo Clinic.
NCT04558307 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04558307 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility of establishing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing at a federally-qualified health center (FQHC) during a global health crisis to mitigate COVID-19 disparities in socioeconomically disadvantaged populations.
Primary Outcome
FQHC staff will complete a comprehensive electronic survey adapted from the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) instrument to assess feasibility of community-engaged research partnership to support testing site (Weiner BJ, et al. Implementation Science. 2017;12(1):108.).
Interventions
- DIAGNOSTIC_TEST Pilot a rapid SARS-CoV-2 testing strategy
- OTHER Community-driven messages to promote COVID-19 testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-06-03 |
| Est. Completion | 2021-06-01 |
What the finished NCT04558307 record still lists
NCT04558307 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Pilot a rapid SARS-CoV-2 testing strategy is the first listed.
NCT04558307 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04558307 about?
NCT04558307 is a clinical study titled "Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations". The purpose of this study is to assess the feasibility of establishing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing at a federally-qualified health center (FQHC) during a global health crisis to mitigate COVID-19 disparities in socioeconomically disadvantaged populations.
What is the current status of trial NCT04558307?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2020-06-03. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT04558307?
The interventions under investigation include: Pilot a rapid SARS-CoV-2 testing strategy (DIAGNOSTIC_TEST), Community-driven messages to promote COVID-19 testing (OTHER).
Who is sponsoring clinical trial NCT04558307?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI